Credit Suisse’s Aquestive Therapeutics AQST Stock Holding History

Credit Suisse’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-28,731	Closed	-$167K	–	3975
2019 Q4	$167K	Buy	+28,731	New	+$149K	﹤0.01%	4017

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's AQST Position: Q1 2020 in Review

Credit Suisse sold out of Aquestive Therapeutics (AQST) in Q1 2020, closing a stake of 28,731 shares — an estimated $167K sold.

Credit Suisse first reported a position in AQST in Q4 2019 and held it in 1 quarter. The position peaked at $167K in Q4 2019. 42 funds tracked by Wall St. Rank hold AQST as of Q1 2020.

Credit Suisse reported no remaining Aquestive Therapeutics position as of Q1 2020 after selling out during the quarter.
Credit Suisse sold 28,731 Aquestive Therapeutics shares in Q1 2020, an estimated $167K.
Credit Suisse first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 1 quarter.
Credit Suisse's Aquestive Therapeutics position peaked at $167K in Q4 2019.
42 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2020.

Based on Credit Suisse's 13F filing for Q1 2020, filed 13 May 2020.